Jazz Pharmaceuticals plc Future Amortization Expense, Year Three (Deprecated 2012-01-31)
Jazz Pharmaceuticals plc (JAZZ) reported Future Amortization Expense, Year Three (Deprecated 2012-01-31) of $4.44 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearThree · last filed 2012-02-28
- Jazz Pharmaceuticals plc future amortization expense, year three (deprecated 2012-01-31) for fiscal 2011 was $4.44M.
| Period end | Future Amortization Expense, Year Three (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | $4.44M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |